Vertex Pharmaceuticals Inc (VRTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $136.56B
Last updated: Nov 17, 2026 at 11:05 AM ET
Vertex Pharmaceuticals Inc (VRTX) Stock Forecast
Analysts expect Vertex Pharmaceuticals (VRTX) to earn $18.12 per share in the fiscal year ending Dec 31, 2026, on revenue of $13.26B. Of 32 analysts, 26 rate the stock Buy or Strong Buy, 4 Hold and 2 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 4 estimates for the fiscal year ending Dec 31, 2026 were revised up and 4 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 32 ratings average 2.09, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 81% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 6 | 18.8% |
| Buy | 20 | 62.5% |
| Hold | 4 | 12.5% |
| Sell | 1 | 3.1% |
| Strong Sell | 1 | 3.1% |
- Consensus
- Buy
- Total analysts
- 32
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 10.1% and revenue estimates rise 10.5%.
- Fiscal year ending Dec 31, 2026
- $18.12
- EPS consensus, revenue $13.26B
- Fiscal year ending Dec 31, 2027
- $19.95
- EPS consensus, revenue $14.65B
- Next report
- Feb 10, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $18.12 | $17.75 to $19.17 | 25 | $13.26B | $13.18B to $13.40B | 27 |
| Dec 31, 2027 | $19.95 | $17.97 to $21.87 | 25 | $14.65B | $14.01B to $15.23B | 25 |
Quarterly Estimates
The EPS consensus rises from $4.19 for the quarter ending Dec 31, 2026 to $4.68 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $4.19 | $3.71 to $5.32 | 30 | $3.56B | $3.35B to $3.77B | 28 |
| Mar 31, 2027 | $4.68 | $4.18 to $5.28 | 8 | $3.44B | $3.10B to $3.66B | 6 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 8 upward and 12 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 4 | 4 |
| Fiscal year ending Dec 31, 2027 | 3 | 7 |
| Quarter ending Mar 31, 2027 | 1 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 4.9% from $19.05.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $18.12 | $18.72 | $17.14 | $16.85 | $19.05 | -4.9% |
| Fiscal year ending Dec 31, 2027 | $19.95 | $20.42 | $20.22 | $20.23 | $21.80 | -8.5% |
| Quarter ending Mar 31, 2027 | $4.68 | $4.78 | $4.63 | $4.63 | $4.85 | -3.5% |
Frequently Asked Questions About VRTX
What is the VRTX stock forecast?
Consensus analyst estimates put Vertex Pharmaceuticals's EPS at $18.12 for the fiscal year ending Dec 31, 2026, on revenue of $13.26B. The consensus rating from 32 analysts is Buy.
How do analysts rate VRTX stock?
Of 32 analysts covering Vertex Pharmaceuticals, 6 rate it Strong Buy, 20 Buy, 4 Hold, 1 Sell and 1 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from VRTX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $18.12, with estimates from $17.75 to $19.17 from 25 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $19.95, with estimates from $17.97 to $21.87 from 25 analysts.
What revenue do analysts expect from Vertex Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $13.26B, with estimates from $13.18B to $13.40B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $14.65B, with estimates from $14.01B to $15.23B.
How many analysts cover VRTX?
32 analysts rate Vertex Pharmaceuticals stock, and 25 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
VRTX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors